Connect with us

Hi, what are you looking for?

Digital Health

FDA Clears Digital Therapeutic for Abdominal Pain from IBS

MetaMe received FDA clearance for its first digital therapeutic on Tuesday. It uses behavioral therapy to help alleviate abdominal pain symptoms for patients with irritable bowel syndrome. 

FDA Clears Digital Therapeutic for Abdominal Pain from IBS

Irritable bowel syndrome, one of the most commonly diagnosed GI conditions, is estimated to affect roughly 10% of adults in the U.S. The condition, characterized by abdominal pain, bloating, and diarrhea or constipation, can have different triggers for each patient. For example, certain foods, stress, and other factors can cause symptoms to flare up.

MetaMe Health, a startup building an app-based treatment to help alleviate some of these symptoms, recently received FDA clearance for its digital therapeutic, called Regulora. It’s built around research by University of North Carolina psychologist Olafur Palsson, who studies the use of psychological treatments for IBS and other GI disorders.  Although the exact cause of IBS is unknown, one idea is that the connection between the brain and the gut can contribute to symptoms.

The app uses self-directed hypnotherapy, with the idea of bringing people into a state of relaxation, and creating a sense of ease around their condition and symptoms. It’s intended to be used in conjunction with other treatments, which can include dietary changes or medications.

The treatment consists of seven 30-minute sessions of behavioral therapy over a period of 12 weeks. The FDA cleared it based on data from a randomized, controlled trial of 362 people, where half used Regulora for 12 weeks and the control group used a digital program for muscle relaxation therapy.

Both groups saw an improvement in abdominal pain in the four weeks after the treatment period, but the difference between the treatment group and control group was not statistically significant. However, during the final four weeks of treatment, 30.9% of subjects who used Regulora saw an improvement in abdominal pain intensity, compared to 21.5% of subjects in the control group.

A few other companies are also working on digital treatments for IBS. For instance, Parallel, which was cleared by the FDA a year ago, also is focused on using cognitive behavioral therapy for IBS. Meanwhile, startup Oshi Health recently raised $23 million for its virtual care platform, which connects patients to gastroenterologists, dieticians, mental health providers and health coaches to help them manage GI conditions.

Seen on MedCity News: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Exclusives

IoT is transforming healthcare through wearables, SaMD, and AI. MedTech needs strong branding for the efficiency and cost savings this will provide.

Digital Health

The lack of standardization is a huge problem in the diagnosis and tracking of neurological disorders: because they are so complex and often slow...

FDA

System creates 3D models of the heart with unprecedented anatomical details, allowing physicians to better plan and personalize therapeutic interventions

FDA

Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV, a tension-activated breakaway safety release valve designed to reduce the...

You May Also Like

Exclusives

Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm. Innovators across the HealthTech...

Exclusives

PRIA clients are provided a high-touch, white-glove service to support their patient access services.

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.